Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study.

ABSTRACT:

Background

Omalizumab may modulate airway remodeling in severe asthma. Using forced expiratory volume in 1 second (FEV₁) as a surrogate of airway remodeling, we aimed to investigate if an omalizumab add-on in severe allergic asthma may lead to a persistent reversal of airway obstruction and to evaluate the potential biomarkers of airway obstruction reversibility.

Methods

Data were collected before (T0) and after omalizumab add-on for 1 year (T1, 32 patients), 2 years (T2, 26 patients) and 4 years (T4, 13 patients). All patients had baseline FEV₁ below 80 % predicted (60.5 ± 12.5 %). After omalizumab, 18 patients showed FEV₁ normalization (reversible airway obstruction; RAO+) already at T1 (88.7 ± 14.9 %, p < 0.0001) that persisted up to T4 (8

SUBMITTER: Solidoro P 

PROVIDER: S-EPMC6475845 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature